Skip to main content
Equibles
ELAN logo

ELAN · Elanco Animal Health Inc · Metrics

Track ELAN — free

Use ELAN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ELAN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$22.52 -0.17 (-0.75%) At close · Oct 23
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$11.25B
Shares
499.62M
Volume · Oct 23 4.28M Avg daily vol (3M) 6.21M

ELAN metrics

90 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$22.52
Market cap
$11.25B

Price action

20 metrics
Price change (1W)
-4.4%
Price change (30D)
+0.9%
Price change (3M)
-9.6%
Price change (6M)
-1.0%
Price change (YTD)
-0.5%
Price change (1Y)
+3.4%
Trailing year
Price change (5Y)
-33.6%
52-week high
$26.84
52-week low
$19.80
Change from 52-week high
-16.1%
Change from 52-week low
+13.7%
Annualized volatility
42.1%
Annualized volatility (3M)
37.0%
Beta
1.3
RSI (14D)
45.5
Price vs SMA 50
-3.0%
Price vs SMA 200
-5.4%
Avg volume (3M)
6.21M
Relative volume
0.7
Average dollar volume
$145.74M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
499.62M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.9×
reciprocal yield 34.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
2.2×
reciprocal yield 44.6%
P / book
1.7
reciprocal yield 58.6%
FCF yield
3.4%
TTM · current market cap
Buyback yield
—
P / FCF
29.7
reciprocal yield 3.4%
P / operating cash flow
18.2
reciprocal yield 5.5%
Earnings yield
-1.8%

Historical valuation

8 metrics
P / E historical average (3Y)
79.1×
reciprocal yield 1.3%
P / E historical average (5Y)
79.1×
reciprocal yield 1.3%
EV / revenue historical average (3Y)
2.8×
reciprocal yield 35.2%
EV / revenue historical average (5Y)
3.0×
reciprocal yield 33.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
55.4%
Operating margin
—
Trailing 12 months
Net margin
-4.0%
Gross profit (TTM)
$2.78B
Operating profit (TTM)
—
Net income (TTM)
−$199.00M
Trailing 12 months
Diluted EPS (TTM)
$-0.40
FCF margin
7.5%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$10.04
Gross profit per diluted share (TTM)
$5.55
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.41
Operating cash flow per diluted share (TTM)
$1.23
Free cash flow per diluted share (TTM)
$0.76
Capital expenditures per diluted share (TTM)
$0.48
R&D per diluted share (TTM)
$0.74
Stock compensation per diluted share (TTM)
$0.15
Book value per share
$13.17

Growth

11 metrics
Revenue growth YoY
+10.2%
Year over year
Net income growth YoY
+390.9%
Revenue (TTM)
$5.02B
Trailing 12 months
EPS growth YoY
+450.0%
Shares change YoY
+1.2%
Year over year · more shares
Revenue CAGR (3Y)
+2.2%
Revenue CAGR (5Y)
+7.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+0.4%
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-3.0%
Return on assets
-1.5%
Debt / equity
0.6
Current ratio
2.1
EBITDA (TTM)
—
Free cash flow (TTM)
$379.00M
Quick ratio
1.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$3.39B
Latest balance sheet
Cash & equivalents
$530.00M
Total assets
$13.56B
Total debt
$3.92B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$617.00M
Capital expenditures (TTM)
$238.00M
R&D (TTM)
$371.00M
SG&A (TTM)
$1.52B
Stock compensation (TTM)
$74.00M
R&D / revenue
7.4%
Stock compensation / revenue
1.5%

Ownership (13F)

9 metrics
13F filers
526
13F filer change QoQ
+5
Institutional ownership
113.6%
Conviction holders (share of 13F filers)
0.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.3%
Holder tenure
16.7
Price vs estimated holder cost
+28.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
21.3%

Short interest

3 metrics
Short interest
7.5%
Latest settlement · 6.2 days to cover
Days to cover
6.2d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
$1.47M
Insider-sentiment score
91 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1739104 CUSIP 28414H103 13F (30d) 105 filings 101 filers Visit website Investor relations